+1-206-701-6702
+44-020-8133-4027
+050-5539-1737
+91-848-285-0837
Press Release: Global Extracorporeal Membrane Oxygenation System Market to Surpass US$ 375.1 Million by 2026
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Extracorporeal Membrane Oxygenation (ECMO) System Market Insights
Extracorporeal membrane oxygenation system is a life supporting system providing cardiac and respiratory support to the patients suffering from severe respiratory failure. ECMO circuit comprises cannulas, pump, blender and oxygenator, which oxygenates the blood and remove carbon dioxide through extracorporeal gas exchange device referred as membrane oxygenator. The location of drainage and reinfusion port of cannulas determines the modality of the ECMO system. If drainage and reinfusion both are from central veins it is referred as venovenous ECMO or if it is from vein to artery it is referred to as venoarterial ECMO. Potential indications for which ECMO is used includes severe acute respiratory distress syndrome (ARDS), acute hypercapnic respiratory failure, to bridge lung transplantation, primary graft dysfunction post-lung transplantation, and pulmonary hypertension with right ventricular failure.
The global ECMO system market was valued at US$ 248.2 million in 2017, and is expected to witness a CAGR of 5.3 % over the forecast period (2018 – 2026).
Figure 2. Global Extracorporeal Membrane Oxygenation System Market, By Modality
Prevalence of Cardiac and Respiratory Diseases are Boosting Growth of the Extracorporeal Membrane Oxygenation System Market
Increasing cases of cardiovascular and respiratory disorders is one of the major factors that is boosting growth of the ECMO system market. For instance, according to World Health Organization (WHO), around 31% of total global deaths was due to cardiovascular disease in 2015, which accounted to nearly 17.7 million deaths. According to European Heart Network AISBL, about 3.9 million and over 1.8 million deaths occurs every year in Europe and European Union respectively, which accounted to nearly 45% of all deaths in European Union. Another factor expected for the growing success of ECMO system market over the forecast period is the rising number of organ transplant surgeries across the globe. For instance, according to Organ and Tissue Authority of Australian Government, the number of surgeries performed for organ transplant in 2017 were around 1,469. Moreover, according to Australia and New Zealand Organ Donation Registry around 1,400 Australians are waiting for organ transplant at any given time.
Also, high prevalence of diseases will lead to increasing demand for extracorporeal membrane oxygenation system in hospitals and surgical centers. For instance, according to annual international registry by Extracorporeal Life Support Organization (ELSO), 65,171 patients received ECMO system in 2015, which increased to 98,840 patients in 2018 out of which 40,256 were neonatal, 22,952 pediatrics, and 35,632 adults.
On the basis of region, extracorporeal oxygenation system market is segmented into North America, Latin America, Europe, Africa, Asia Pacific, and Middle East. North America is leading the ECMO system market, owing to various factors such as well-established healthcare infrastructure, government funds, and reimbursement framework. Moreover, high pool of Chronic Obstructive Pulmonary Disease (COPD) and other disorders are expected to fuel market growth in this region. Furthermore, around 85 million and 49 million people were suffering from cardiovascular disease in Europe and European Union, respectively in 2015. According to Centers for Disease Control and Prevention (CDC), COPD was the third leading cause of death with more than 15 million Americans diagnosed with COPD every year in 2011. Furthermore, Asia Pacific region is expected to gain significant traction in ECMO system market, attributed by advancements in healthcare system with support of government initiatives.
Industrial Collaboration by the Key Players is Fueling Extracorporeal Membrane Oxygenation System Market
The global extracorporeal membrane oxygenation system market is operated by Medtronic Plc., Getinge Group, LivaNova Plc., Terumo Corporation, Xenios AG, Microsoft Scientific Co., Origen Biomedical, Eurosets S.R.L., Nipro Corporation and Alung technologies Inc. The industry players are adopting the strategy of collaboration focusing on development of new products. For instance, in 2018, Medtronic Plc. collaborated with the Sayler Biomedical LLC, for the development of their product Century heart Lung machine. The collaboration has made the Medtronic’s product available for customers globally. Century heart lung machine has features, such as compact and sturdy design, easy to use components and affordable price. This is expected to strengthen customer base and widen the product portfolio of Medtronic.
Extracorporeal membrane oxygenation (ECMO) assists cardiopulmonary functions outside the body. Based on the location of drainage and reinfusion there are 3 different types of extracorporeal membrane oxygenation system which are arteriovenous, venoarterial and venovenous whereas on the bases of age, it is classified into neonatal, pediatric and adult. The growing number of congenital heart defects, increase the demand for ECMO. For instance, according to American Heart Association, approximately 40,000 babies are born with a congenital heart defect in United States each year and around 2 to 3 million individuals are living with a congenital heart defect.
Market Dynamics
The growth of ECMO market is due to factors like increasing prevalence of cardiovascular and chronic respiratory disease such as asthma, chronic obstructive pulmonary disease (COPD), occupational lung disease or pulmonary hypertension. For instance, in 2014, Centers for Disease Control and Prevention (CDC) reported 1,417,101 deaths globally due to chronic respiratory disease. Moreover, increasing implementation of ECMO will also swell the ECMO system market. According to National Center for Biotechnology Information, ECMO is effective and growing means of life support for the patients with swine flu infection by bridging the gap, between respiratory distress to total body recovery. Further, medical policies such as Premera, supports extracorporeal membrane oxygenation (ECMO) in adults may be considered medically necessary for the management of acute respiratory failure. On the flip side of the coin, the ECMO system market is expected to be hampered by the complications associated with the ECMO system such as internal bleeding, blood clotting or technical failure.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 36 market data tables and 32 figures on "Extracorporeal Membrane Oxygenation System Market - Global forecast to 2026”.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
